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Resting heart rate is significantly associated with cardiovascular morbidity and mortality. However, the extent to
which resting heart rate is genetically determined is poorly understood, and no genes have been found that contribute
to variation in resting heart rate. Because signaling through the b1 adrenergic receptor is a key determinant of
cardiac function, we tested whether polymorphisms in this receptor are associated with resting heart rate. A cohort
of 11,000 individuals of Chinese and Japanese descent, from nuclear families, was genotyped for twopolymorphisms,
resulting in a serine/glycine substitution at amino acid 49 (Ser49Gly) and an arginine/glycine substitution at residue
389 (Arg389Gly), in the b1 adrenergic receptor. For comparison, polymorphisms in the b2 and b3 adrenergic
receptors were also evaluated. The Ser49Gly polymorphism was significantly associated ( ) with restingPp .0004
heart rate, independent of other variables, such as body-mass index, age, sex, ethnicity, exercise, smoking, alcohol
intake, hypertension status, and treatment with beta blockers. The data support an additive model in which
individuals heterozygous for the Ser49Gly polymorphism had mean heart rates intermediate to those of either type
of homozygote, with Ser homozygotes having the highest mean heart rate and with Gly homozygotes having the
lowest. Neither the Arg389Gly polymorphism in the b1 adrenergic receptor nor polymorphisms in the b2 and b3
adrenergic receptors were associated with resting heart rate. The heritability of heart rate was 39.7% 7.1%
( ).57P ! 10
Introduction
Resting heart rate is significantly correlated with car-
diovascular morbidity and mortality (Dyer et al. 1980;
Kannel et al. 1987; Gillman et al. 1993; Greenland et
al. 1999; Kristal-Boneh et al. 2000). For example, in the
Framingham study, in a sample of 15,000 subjects who
did not have cardiovascular disease at the time of entry
into study, cardiovascular and coronary mortality in-
creased progressively with resting heart rate, thus sup-
porting a causal relationship between heart rate and sub-
sequent development of heart disease (Kannel et al.
1987). More recently, another follow-up study, com-
Received October 30, 2001; accepted for publication January 10,
2002; electronically published February 18, 2002.
Address for correspondence and reprints: Dr. Koustubh Ranade,
Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box
5400, Princeton, NJ 08543-5400. E-mail: koustubh.ranade@bms
.com; or Dr. Neil Risch, Department of Genetics, Stanford University
School of Medicine, Stanford, CA 94305-5120. E-mail: risch@lahmed
.stanford.edu
* Present affiliation: Bristol-Myers Squibb, Pharmaceutical Re-
search Institute, Princeton, NJ.
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7004-0011$15.00
prising 13,000 Israeli men who were free of cardiovas-
cular disease at the time of entry into study, indicated
that resting heart rate was significantly associated with
cardiovascular mortality after other risk factors had
been controlled for (Kristal-Boneh et al. 2000).
These observations suggest that knowing the genetic
determinants of heart rate might provide clues to the
etiology of heart disease and even permit the identifi-
cation of individuals at elevated risk of development of
heart disease. Recent studies indicate that, at least in
some white populations, genes explain a significant pro-
portion of the variation seen in resting heart rate (Ditto
1993; Singh et al. 1999); however, the general appli-
cability of these estimates of heritability is not known.
Furthermore, specific genes that make a significant con-
tribution to heart rate are also not known. In contrast,
numerous studies have revealed other factors—such as
cigarette smoking, regular physical activity, stress, hy-
pertension, and treatment with beta blockers—that in-
fluence heart rate (Blackburn et al. 1960; Thomas 1960;
Higgins and Kjelsberg 1967; Goldbourt and Medalie
1977; Manuck and Garland 1980; Gillum 1988; The
Beta-Blocker Evaluation of Survival Trial Investigators
2001).
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Cardiac function is regulated by a variety of mech-
anisms. However, it appears that epinephrine and nor-
epinephrine, acting through specific b-adrenergic recep-
tors, play a critical role in regulating both the frequency
and the force of contraction of the heart (Insel 1996).
On the basis of their ability to distinguish different li-
gands, beta-adrenergic receptors can be divided into
three types. The b1 adrenergic receptor is the predom-
inant subtype expressed in the heart, and a number of
studies have made it clear that signaling through this
receptor subtype is important for both cardiac chron-
otropy and cardiac inotropy (Rohrer et al. 1996, 1999;
Engelhardt et al. 1999). Moreover, signaling through
the b1 adrenergic receptor is decreased in the failing
heart (Bristow et al. 1986, 1993). The b2 adrenergic
receptor is thought to regulate vascular smooth-muscle
relaxation, and the b3 adrenergic receptor has been im-
plicated in the control of lipolysis in adipose tissue.
For these reasons, we hypothesized that polymor-
phisms in the b1 adrenergic receptor might contribute
to variation in resting heart rate. The large sample of
middle-aged individuals of Chinese and Japanese origins
whom we have collected in an effort to identify genes
for essential hypertension and related phenotypes have
provided an opportunity to test this hypothesis. Here
we show that a single-nucleotide polymorphism (SNP)
that results in a serine/glycine amino acid substitution
in the b1 adrenergic receptor is associated with resting
heart rate in this population.
Subjects and Methods
Subjects
Individuals were recruited as part of the Stanford,
Asia, Pacific Program for Hypertension and Insulin Re-
sistance (SAPPHIRe), and details of this study popula-
tion have been published elsewhere (Ranade et al. 2000).
In brief, hypertensive subjects of Chinese and Japanese
origins were recruited in the San Francisco Bay Area,
Hawaii, and Taiwan. Hypertension was defined as in-
cluding blood pressure (BP) in the upper 20% of the BP
distribution of untreated individuals. In our study pop-
ulation, this threshold translated into the following val-
ues: (a) systolic BP (SBP) 160 mmHg and/or diastolic
BP (DBP) 95 mmHg or (b) treatment with two med-
ications for high blood pressure (stage II hypertension).
Alternatively, the subject had uncontrolled hyperten-
sion—that is, was taking one medication for high blood
pressure and had either systolic BP 140 or diastolic
90 mmHg. Comparably hypertensive siblings of the
proband, as well as low-normotensive sibs were also
recruited. “Low-normal” BP was defined as BP in the
bottom 30% of the age- and sex-adjusted BP distribu-
tion, which, in our study population, translated into the
following BP values: for men !45 years of age, low-
normal BP was defined as systolic BP 115 mmHg and
diastolic BP 76; for men 145 years of age, systolic BP
122 and diastolic 78; for women !45 years of age,
systolic BP 107 and diastolic BP 70 mmHg; and, for
women 145 years of age, systolic BP 118 and diastolic
BP 75. Individuals with chronic illnesses such as dia-
betes or heart, liver, or kidney diseases or cancer were
excluded from the study; however, individuals in whom
diabetes had been diagnosed as a result of tests per-
formed by us were not excluded.
Resting heart rate and resting blood pressure were
determined simultaneously, by use of an oscillometric
device, the Dinamap model 1846 SX (Critikon). The
subject was seated with legs uncrossed and was asked
to refrain from talking for 5 min. Blood-pressure and
heart-rate measurements were taken three times, with at
least a 1-min time lapse between two consecutive read-
ings, and the average of the second and third readings
was used in the analysis. To ensure uniform measure-
ments at the different sites, technicians/clinicians at all
the sites were trained to measure BP by use of this pro-
tocol, and they were monitored annually during site vis-
its. Furthermore, there was a centralized retraining and
recertification of key technicians each year.
In this study, 1,348 individuals were evaluated. The
distribution of family sizes was as follows: 199 single-
tons and 252, 120, 41, 17, and 6 families with two,
three, four, five, and six sibs, respectively.
This study was approved by institutional review
boards at all participating sites, and informed consent
was obtained from all subjects.
Genotyping
Genotyping was performed by the TaqMan assay, as
described elsewhere (Ranade et al. 2001). Subjects were
typed for two polymorphisms that result in serine/glycine
(Ser49Gly) and arginine/glycine (Arg389Gly) amino acid
substitutions at residues 49 and 389, respectively (Ma-
qbool et al. 1999; Mason et al. 1999). Three polymor-
phisms in the b2 adrenergic receptor were evaluated. One
is a C/T transition (C-47T) in the leader cistron (McGraw
et al. 1998). The other two result in glycine/arginine
(Gly16Arg) and glutamate/glutamine (Glu27Gln) amino
acid substitutions at residues 16 and 27, respectively
(Reihsaus et al. 1993). A polymorphism in the b3 adre-
nergic receptor, which results in a tryptophan/arginine
(Trp64Arg) amino acid substitution at residue 64 (Wal-
ston et al. 1995), was also examined. The probes and
primers used in the TaqMan assay were as follows (in
each probe, the polymorphic nucleotide is underlined).
For the SNPs in the b1 adrenergic–receptor gene, the
probes and primers were as follows: for Ser49Gly, the
probes were CCAGCGAAAGCCCCGAGCC and CCA-
GCGAAGGCCCCGAGC, and the primers were GTCG-
CCGCCCGCCTCGTT and CCATGCCCGCTGTCCA-




Sex (M/F) 493/529 137/189
Affection status:
Low normotensive 321 38
Hypertensive 701 288
Medication statusa 612 260
Mean age  SD (years)b 49.8  8.3 55.2  8.1
Mean BMI  SD (kg/m2)b 25.4  3.4 26.5  3.7
a Number of patients with hypertension who are taking
antihypertensive medication.
b The mean for the low-normotensive group was 47.3
 7.6 years; that for the hypertensive group was 52.3
8.3 years.
CTGCT; and, for Arg389Gly, the probes were AGG-
CCTTCCAGCGACTGCTCTGC and AGGCCTTCC-
AGGGACTGCTCTGCT and the primers were GGCCT-
TCAACCCCATCATCTA and CCGGTCTCCGTGGG-
TCGCGT. For SNPs in the b2 adrenergic–receptor gene,
the probes and primers were as follows: for C-47T, the
probes were CGCCTCAGCGGGCGGACCC and CGC-
CTCAGCAGGCGGACCC, and the primers were GCT-
GAATGAGGCTTCCAGGCGT and GCGCGCAGTCT-
GGCAGGTAA; for Gly16Arg, the probes were CGC-
ATGGCTTCCATTGGGTGC and CGCATGGCTTCT-
ATTGGGTGC, and the primers were GGAACGGCAG-
CGCCTTCT and CAGGACGATGAGAGACATGAC-
GAT; and, for Glu27Gln, the probes were CTCGTCCC-
TTTCCTGCGTGACGT and CTCGTCCCTTTGCTG-
CGTGACGT (the primers used in this assay were the
same as those used for Gly16Arg). For the Trp64Arg SNP
in the b3 adrenergic receptor, the probes were TCTCGG-
AGTCCAGGCGATGGCCA and CTCGGAGTCCGG-




Heart rates were natural-log transformed to approx-
imate normality and then were used in the statistical
analysis. In a preliminary analysis, the effect that the b
adrenergic receptor has on resting heart rate was ex-
amined by one-way analysis of variance. Significant re-
sults were then followed up by multivariate analysis, as
described below. Heritability of resting heart rate was
estimated by the program SOLAR, with the entire sib-
ship being considered in the analysis, under the as-
sumption of a multivariate normal distribution (Almasy
and Blangero 1998). The influence that the b1 adrener-
gic–receptor genotype and other covariates have on rest-
ing heart rate was estimated simultaneously in a mul-
tivariate analysis, also by the program SOLAR. In
addition to the b1 adrenergic–receptor genotype, this
analysis included, as covariates, BMI, age, sex, ethnicity,
hypertension status, antihypertensive medications (beta
blockers, ACE inhibitors, calcium-channel blockers, and
diuretics), smoking, alcohol intake, and exercise. SO-
LAR estimates what proportion of variance is explained,
in the presence of background polygenic variance, by a
covariate, thus allowing for familial correlation in heart
rate. The program also takes into account the nonin-
dependence of sib genotypes. Smoking and alcohol use
were evaluated as continuous variables, as number of
cigarettes per day and number of drinks per month, re-
spectively. We derived a measure of physical activity,
essentially as described by Ainsworth et al. (2000), and
used this metric in the analysis.
For estimation of linkage disequilibrium between
SNPs, one individual was chosen at random from each
of the families studied, and pairwise haplotype frequen-
cies were estimated on the basis of data from these 635
individuals, by the expectation-maximization algorithm
as implemented in the EH program (see the Web site of
the Lab of Statistical Genetics at Rockefeller University).
Linkage-disequilibrium values (D′) were calculated as
described elsewhere (Lewontin 1964).
Results
We evaluated 1,348 subjects in this study (for details of
the study population, see table 1). On the basis of cor-
relations within entire sibships, we estimate the herita-
bility of heart rate at 39.7%  7.1% ( ) in our7P ! 10
study population, an estimate similar to that derived in
the Framingham study (∼46%) (Singh et al. 1999).
We typed subjects for two polymorphisms in the b1
adrenergic–receptor gene; the first polymorphism re-
sulted in a serine/glycine amino acid substitution at po-
sition 49 (Ser49Gly), and the second resulted in an ar-
ginine/glycine substitution at position 389 (Arg389Gly).
We evaluated the influence that these polymorphisms
had on heart rate, in a multivariate analysis that in-
cluded, as covariates, BMI, age, ethnicity, sex, cigarette
smoking, alcohol intake, exercise, antihypertensive-
medication use, and hypertension status.
The Ser49Gly polymorphism was significantly asso-
ciated ( ) with resting heart rate (table 2). In-Pp .0004
dividuals homozygous for the Ser allele had the highest
mean heart rate (69.4 beats per minute [bpm]), hetero-
zygotes had an intermediate heart rate (67.7 bpm), and
Gly homozygotes had the lowest heart rate (64.2 bpm).
These observations suggest an additive model, with every
Ser allele increasing heart rate. The polymorphism ap-
peared to have a significant impact on heart rate, because
the difference, in mean values, between the two classes
of homozygotes was almost half a standard deviation.
The Arg389Gly variant, in contrast, was not associated
( ) with resting heart rate. Consistent with theseP 1 .05
results, there was only weak linkage disequilibrium be-
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Table 2
Mean Heart Rate, by b Adrenergic–Receptor Genotype
ADRENERGIC-RECEPTOR
GENE AND SNP
MEAN HEART RATE  SD(N)a
(bpm)
PbGenotype 1/1 Genotype 1/2 Genotype 2/2
b1:
Ser49Gly 69.4  11.0 (996) 67.7  10.8 (317) 64.2  9.8 (35) .0004
Arg389Gly 68.7  11.14 (782) 68.6  10.6 (489) 72.0  11.8 (77) .68
b2:
C-47T 67.6  8.7 (12) 66.4  11.2 (149) 68.8  11.1 (850) .06
Gly16Arg 68.8  11.1 (292) 68.3  10.9 (665) 69.7  11.0 (374) .17
Glu27Gln 68.2  8.3 (15) 68.3  10.8 (185) 69.0  11.1 (1,145) .74
b3:
Trp64Arg 68.8  10.9 (942) 69.2  11.3 (368) 67.0  8.7 (26) .57
a All statistical inferences are based on log-transformed heart rates, but, for clarity, heart rates in the
untransformed scale are given.
b Values for b1 adrenergic receptor SNPs are obtained from a multivariate analysis; for the other SNPs,
values are from one-way analysis of variance (see the “Statistical Analysis” section and table 3). For each
SNP, 1/1 denotes homozygosity for the first amino acid or base pair listed in the leftmost column, 1/2
denotes heterozygosity, and 2/2 homozygosity for the second amino acid or base pair listed in the leftmost
column; thus, for the Ser49Gly SNP, 1/1 p Ser/Ser, 1/2 p Ser/Gly, and 2/2 p Gly/Gly.
Table 3
Influence of Covariates, Including Ser49Gly




















NOTE.—Heart rate and the other covariates noted
above were analyzed simultaneously in a multivar-
iate model using SOLAR. The regression coefficients
and their SEs, for age, sex, ethnicity, hypertension
status, and beta-blocker use, were 0.127 (0.037),
0.814 (0.570), 2.758 (0.782), 3.054 (0.725), and
5.068 (0.608), respectively. The categorical vari-
ables were coded as follows: sex—malep 0, female
p 1; ethnicity—Chinese p 0, Japanese p 1; hy-
pertension status—unaffected p 0, affected p 1;
and beta-blocker use—untreated p 0, treated p 1.
tween the Ser49Gly and Arg389Gly variants ( ′D p
; ) in our study population.20.29 x p 39.181 df
For comparison, we also examined, for association
with resting heart rate, polymorphisms in the b2 and
b3 adrenergic receptors (table 2). These analyses in-
cluded glycine/arginine (Gly16Arg) and glutamate/glu-
tamine (Glu27Gln) polymorphisms at residues 16 and
27, respectively, in the b2 adrenergic receptor and a
third polymorphism (C-47T) in the leader cistron of this
gene. For the b3 adrenergic–receptor gene, we evaluated
a tryptophan/arginine (Trp64Arg) polymorphism at res-
idue 64. As expected, there was no evidence of asso-
ciation between these polymorphisms and resting heart
rate.
As shown in table 3, age, ethnicity, and hypertension
status were strongly predictive ( ) of restingP ! .0001
heart rate; sex was less significantly associated (Pp
). BMI, smoking, alcohol intake, and exercise were.001
not significantly associated with heart rate, however. As
expected, use of beta blockers was highly significantly
associated with heart rate. Hypertensive subjects re-
ceiving beta-blocker therapy had a lower mean heart
rate (65.3 bpm) than did those receiving other types of
antihypertensive medication (69.8 bpm) ( ). Use7P ! 10
of other antihypertensive medicines that were frequently
prescribed (i.e., calcium-channel blockers, ACE inhibi-
tors, and diuretics) was not associated with heart rate,
however.
We stratified the population on the basis of ethnicity,
the site where subjects were recruited, and medication
status, and we examined mean heart rates by genotype
(table 4). In general, subjects with the Ser/Gly or Gly/
Gly polymorphism had consistently lower mean heart
rates than did Ser/Ser homozygotes, regardless of eth-
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Figure 1 Cumulative distributions of heart rate, by Ser49Gly
genotype. The solid line indicates results for Ser49 homozygotes, the
dotted line indicates results for Ser/Gly heterozygotes, and the dashed
line indicates results for Gly49 homozygotes. The percentage of in-
dividuals with heart rates lower than a certain value can be read off
the Y-axis.
Table 4
b1 Adrenergic–Receptor Genotypes and Heart Rates, Stratified by Ethnicity, Geographical Origin, and Medication Status
and within Sibships
STRATUM




Chinese 70.3  11.1 (749) 68.2  10.7 (251) 65.2  6.6 (22)
Japanese 66.7  10.4 (247) 65.6  11.1 (66) 62.4  13.8 (13)
Site:
San Francisco Bay 63.4  8.6 (95) 62.4  8.1 (36) 58.0  9.5 (3)
Hawaii 66.9  10.5 (258) 66.1  11.8 (79) 63.7  15.0 (10)
Taiwan:
Tri-Services General Hospital, Taipei 70.7  10.6 (161) 66.7  8.5 (47) 67.3  7.0 (10)
National Taiwan University, Taipei 70.4  11.2 (145) 72.0  12.0 (38) NA
Veterans General Hospital, Taipei/Taichung 72.0  11.2 (337) 69.3  10.5 (117) 63.5  6.0 (12)
Overall 71.3  11.1 (643) 69.2  10.5 (202) 65.2  6.6 (22)
Medication:
Unmedicated:
Low normotensive 70.1  9.3 (277) 68.4  9.3 (75) 66.3  5.6 (7)
Hypertensive 74.4  12.0 (93) 74.0  15.3 (23) 76.0 (1)
Hypertensive subjects taking antihypertensive medication 68.3  11.4 (626) 66.7  10.5 (219) 63.2  10.5 (27)
Sibships:
Families with Ser/Gly subjects 68.8  9.5 (165) 67.7  11.2 (165) 64.7  5.7 (16)
a NA p not applicable (there were no Gly/Gly homozygotes at this site).
nicity, geographic origin, or medication status. The ex-
ceptions were the small number of unmedicated hyper-
tensive individuals (UH [ ]) and the groupNp 117
recruited at National Taiwan University (NTU [Np
]). This apparent inconsistency is almost certainly183
due to the small sample size of each group. When the
cohort from Taiwan was examined as a whole, mean
heart rates for the three different genotypeswere entirely
consistent with those seen at the other sites. Further-
more, the difference, in mean heart rates, between Ser49
homozygotes and heterozygotes in both strata, com-
pared to that in the complementary strata, is not sta-
tistically significant (K.R. and N.R., unpublished ob-
servations). Thus, there is no evidence of heterogeneity
among any of the defined strata. We also examined sib-
ships that had at least one Ser/Gly heterozygote and one
of the other genotypes—that is, families that were seg-
regating the minor Gly49 allele. As in the overall sam-
ple, Ser/Gly heterozygotes and Gly/Gly homozygotes
had lower mean heart rates than did Ser/Ser homozy-
gotes. Taken together, these results suggest that the as-
sociation between the Ser49Gly SNP and heart rate is
unlikely to be confounded by either population strati-
fication or antihypertensive medication (specifically,
treatment with beta blockers). It is noteworthy that the
magnitude of the effect that the Ser49Gly genotype had
on heart rate was the same in both the low-normoten-
sive group comprising 1350 individuals and in the hy-
pertensive group (see table 4). In both groups, the dif-
ference, in heart rates, between Gly/Gly homozygotes
and Ser/Ser homozygotes was approximately half a
standard deviation.
We next compared the distributions of heart rates for
the three Ser49Gly genotypes (fig. 1). It appeared that
the entire distributions of the Ser/Gly and Gly/Gly gen-
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Table 5
b1 Adrenergic–Receptor Genotypes and Blood Pressure
SNP AND
GENOTYPE
MEAN BLOOD PRESSURE  SD(N)
(mmHg)
Low Normotensive Hypertensivea
Systolic Diastolic Systolic Diastolic
Ser49Gly:
Ser/Ser 104.8  8.1 (277) 65.0  6.5 (277) 141.2  22.9 (719) 82.7  12.9 (719)
Ser/Gly 103.6  10.7 (75) 64.1  7.8 (75) 141.6  19.7 (242) 83.1  11.2 (242)
Gly/Gly 99.3  6.3 (7) 62.6  5.2 (7) 132.8  20.0 (28) 78.4  11.0 (28)
Arg389Gly:
Arg/Arg 104.1  9.3 (198) 64.5  6.9 (198) 140.6  21.5 (584) 82.4  12.1 (584)
Arg/Gly 104.6  8.1 (138) 64.8  6.5 (138) 141.9  23.2 (351) 82.8  13.2 (351)
Gly/Gly 106.7  6.5 (23) 66.1  7.0 (23) 140.8  21.9 (54) 84.4  11.7 (23)
a Blood-pressure readings of these individuals are distorted by antihypertensive medications.
otypes were shifted toward lower heart rates, although
the effect was most apparent for the Gly/Gly genotype.
A very recent study from Sweden has suggested that
homozygosity for the Arg allele of the Arg389Gly poly-
morphism of the b1 adrenergic receptor is associated
with hypertension (Bengtsson et al. 2001). In our study
population, however, the Arg allele was not associated
with either increased blood pressure or hypertension
status (table 5). In contrast, homozygosity for the Gly
allele of the Ser49Gly polymorphism was associated
with modestly decreased blood pressures. This obser-
vation is consistent with the lower heart rates of Gly49
homozygotes. This decrease in blood pressure, however,
was not statistically significant.
Discussion
We have evaluated two polymorphisms in the b1 ad-
renergic receptor—which result in serine/glycine and ar-
ginine/glycine amino acid substitutions at positions 49
and 389, respectively—for association with resting heart
rate. The Ser49Gly variant was significantly associated
( ) with heart rate, independent of other var-Pp .0004
iables—such as age, sex, ethnicity, hypertension status,
and beta-blocker use—that also had a significant influ-
ence on heart rate. Remarkably, the effect that the
Ser49Gly genotype had on heart rate was similar to that
of beta-blocker therapy—that is, homozygosity for the
Gly49 allele and beta-blocker use both decreased heart
rate by ∼5 bpm. In contrast, the Arg389Gly variant was
not significantly associated with heart rate. However, we
note that Gly389 homozygotes had a higher mean heart
rate than did the subjects with either of the other two
genotypes (table 2). If, as these data suggest, the Gly389
allele is recessive, then the lack of a significant effect
might be due to the small number of Gly389 homozy-
gotes in our study.
In contrast to the association between Ser49Gly ge-
notype and resting heart rate, there was no evidence of
association between polymorphisms in the b2 and b3
adrenergic receptors and heart rate. These results un-
derscore the importance that signaling through the b1
adrenergic receptor has for cardiac function, and they
further highlight the difference among these b adrener-
gic–receptor subtypes.
The association between Ser49Gly genotype and rest-
ing heart rate is robust to population stratification, be-
cause the Gly49 allele consistently decreased heart
rate—regardless of ethnicity or site of recruitment and,
perhaps most importantly, even within sibships that
were segregating the Gly49 allele (table 4). The asso-
ciation also is robust to confounding by the use of beta
blockers, for two reasons. First, Ser49Gly genotype was
significantly associated with resting heart rate even
when beta-blocker use was a covariate in the analysis,
indicating that Ser49Gly genotype is associated with
heart rate, independent of treatment with beta blockers
(table 3). Second, the magnitude of the effect that the
Ser49Gly genotype has on heart rate was similar (ap-
proximately half a standard deviation) in the large num-
ber of low-normotensive subjects ( ) who wereNp 359
not treated with beta blockers and in the hypertensive
group taking beta blockers (table 4). The similar effect
that this SNP has on heart rate in both the low-nor-
motensive and hypertensive groups, together with the
fact that our study population is middle-aged (average
age 47.3 and 52.3 years for the low-normotensive and
hypertensive groups, respectively), suggests that the as-
sociation between Ser49Gly and heart rate might be
generalizable to the population at large.
The Gly49 residue is evolutionarily highly conserved
from rat through human (Podlowski et al. 2000), sug-
gesting that replacing this residue with serine could af-
fect the function of the b1 adrenergic receptor. Since
this amino acid residue is in the extracellular portion
of the receptor—and is not in proximity to the hormone-
binding site—an appealing hypothesis is that this resi-
due is important for receptor trafficking, perhaps af-
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fecting the number of functional molecules on the
surface of the cell. This mechanism would be consistent
with the dosage effect that the polymorphism has on
heart rate. It is possible, however, that the Ser49Gly
variant is in tight linkage disequilibrium with another
SNP that is, in fact, functionally associated with heart
rate. Further studies—of nucleotide variation in the b1
adrenergic–receptor gene and of the impact that the
Ser49Gly variant has on the function of the recep-
tor—will be needed to resolve this issue.
On the basis of the strong association between ele-
vated resting heart rate and cardiovascular mortality
and our observations that Ser49 homozygotes had
higher heart rates, we might expect these individuals to
be more susceptible to cardiovascular mortality and
Gly49 carriers to be protected from it. We could not
address this question, because subjects with overt heart
disease were intentionally excluded from our study.
However, while this work was in progress, another
study reported an association between the Ser49Gly var-
iant and survival times in patients with heart failure.
Consistent with our expectation, subjects with a Gly49
allele had better survival rates than did Ser49 homo-
zygotes (Borjesson et al. 2000). A second study sug-
gested that the Gly49 allele was associated with idio-
pathic dilated cardiomyopathy; however, this finding
was based on the study of only 37 patients (Podlowski
et al. 2000). In contrast—and consistent with our results
showing that the Arg389Gly variant has no effect on
heart rate—another case-control study found no evi-
dence of association between this polymorphism and
dilated cardiomyopathy (Tesson et al. 1999). Larger
studies with sufficient numbers of Gly49 and Gly389
homozygotes will be needed to adequately address this
issue.
It is interesting to note that beta blockers decreased
heart rate by ∼5 bpm, regardless of the Ser49Gly ge-
notype. In contrast, subjects homozygous for the
Gly389 allele had a smaller reduction (1.5 bpm) in heart
rate than did either Arg389 homozygotes or heterozy-
gotes (5 bpm). This difference was not statistically sig-
nificant, perhaps because of the small number of Gly389
subjects. However, this observation, as well as the fact
that the Arg389Gly polymorphism is known to affect
the interaction between the receptor and a downstream
G-protein (Mason et al. 1999), raises the intriguing pos-
sibility that Gly389 homozygotes respond differently to
beta blockers.
In summary, we have shown both significant herita-
bility (∼40%) of resting heart rate and a significant as-
sociation between b1 adrenergic–receptor genotype and
heart rate. The extent to which polymorphisms in this
gene influence susceptibility to and progression of heart
failure and other cardiovascular morbidity and mor-
tality remains to be determined.
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